Medimmune Limited

Research Development Foundation

Astrazeneca Ab

Yariv Mazor

Scott A Hammond

Srinath Kasturirangan

George Georgiou

Changshou Gao

Claire Louise Dobson

Ronald Herbst

Godfrey Rainey

Darren Schofield

Stacey Drabic

Michelle Morrow

Brian Lobo

Michael Oberst

Prakash Manikwar

Jonathan Seaman

Simon Dovedi

Gianluca Carlesso

Kristen Pollizzi

Partha S Chowdhury

Nazzareno Dimasi

Qun Du

Vaheh Oganesyan

Gordon Moody

Andrew Grier Buchanan

Chunning Yang

Frank Irvine Comer

Yue Wang

Deepali Malhotra

Michael Overstreet

Karin Lee

Stacy Pryts

Eleanor Clancy-thompson

The present disclosure relates to antibody molecules that bind epidermal growth factor receptor (EGFR) and/or c-Met and conjugates containing these antibody molecules. The antibody molecules and conjugates find application in the treatment of cancer, for example.

Antibody molecules and conjugates

The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides for specific binding proteins, including antibodies, which bind to a target protein. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making such proteins. The disclosure provides methods of inducing an immune response in a subject as well as methods for treating or preventing cancer in a subject by administering the proteins, nucleic acid molecules and/or compositions to the subject.

Bispecific binding proteins and uses thereof

The disclosure relates to binding proteins, including antibodies, that bind to Programmed Death-1 ('PD-1') and T cell immunoreceptor with Ig and ITIM domains (“TIGIT”). The disclosure also provides compositions comprising such binding proteins and nucleic acid molecules encoding such binding proteins. The disclosure further relates to methods of treating a disorder or condition using such binding proteins.

Bispecific PD-1 and TIGIT binding proteins and uses thereof

The technology relates in part to engineered antibodies. In particular, multispecific engineered antibodies. Such antibodies can be utilized for diagnostic and therapeutic applications in some aspects.

Modified polypeptides for bispecific antibody scaffolds

Methods and compositions for the screening and isolation of ligand-binding polypeptides, such as antibodies. In some aspects, methods of the invention enable the isolation of intact soluble antibodies comprising a constant domain. Screening methods that employ genetic packages such as bacteria and bacteriophages enable high through-put identification of ligand binding molecules.

Immunoglobulin libraries

Growing community of inventors

Gaithersburg, MD, United States of America

Yariv Mazor